Clinical characteristics of 134 convalescent patients with COVID-19 in Guizhou, China.
Clinical features
Coronavirus disease 2019 (COVID-19)
Disease severity
Pneumonia
Journal
Respiratory research
ISSN: 1465-993X
Titre abrégé: Respir Res
Pays: England
ID NLM: 101090633
Informations de publication
Date de publication:
26 Nov 2020
26 Nov 2020
Historique:
received:
12
07
2020
accepted:
19
11
2020
entrez:
27
11
2020
pubmed:
28
11
2020
medline:
16
1
2021
Statut:
epublish
Résumé
Previous studies have focused on the clinical characteristics of hospitalized patients with the novel 2019 coronavirus disease (COVID-19). Limited data are available for convalescent patients. This study aimed to evaluate the clinical characteristics of discharged COVID-19 patients. In this retrospective study, we extracted data for 134 convalescent patients with COVID-19 in Guizhou Provincial Staff Hospital from February 15 to March 31, 2020. Cases were analyzed on the basis of demographic, clinical, and laboratory data as well as radiological features. Of 134 convalescent patients with COVID-19, 19 (14.2%) were severe cases, while 115 (85.8%) were non-severe cases. The median patient age was 33 years (IQR, 21.8 to 46.3), and the cohort included 69 men and 65 women. Compared with non-severe cases, severe patients were older and had more chronic comorbidities, especially hypertension, diabetes, and thyroid disease (P < 0.05). Leukopenia was present in 32.1% of the convalescent patients and lymphocytopenia was present in 6.7%, both of which were more common in severe patients. 48 (35.8%) of discharged patients had elevated levels of alanine aminotransferase, which was more common in adults than in children (40.2% vs 13.6%, P = 0.018). A normal chest CT was found in 61 (45.5%) patients during rehabilitation. Severe patients had more ground-glass opacity, bilateral patchy shadowing, and fibrosis. No significant differences were observed in the positive rate of IgG and/or IgM antibodies between severe and non-severe patients. Leukopenia, lymphopenia, ground-glass opacity, and fibrosis are common in discharged severe COVID-19 patients, and liver injury is common in discharged adult patients. We suggest physicians develop follow-up treatment plans based on the different clinical characteristics of convalescent patients.
Sections du résumé
BACKGROUND
BACKGROUND
Previous studies have focused on the clinical characteristics of hospitalized patients with the novel 2019 coronavirus disease (COVID-19). Limited data are available for convalescent patients. This study aimed to evaluate the clinical characteristics of discharged COVID-19 patients.
METHODS
METHODS
In this retrospective study, we extracted data for 134 convalescent patients with COVID-19 in Guizhou Provincial Staff Hospital from February 15 to March 31, 2020. Cases were analyzed on the basis of demographic, clinical, and laboratory data as well as radiological features.
RESULTS
RESULTS
Of 134 convalescent patients with COVID-19, 19 (14.2%) were severe cases, while 115 (85.8%) were non-severe cases. The median patient age was 33 years (IQR, 21.8 to 46.3), and the cohort included 69 men and 65 women. Compared with non-severe cases, severe patients were older and had more chronic comorbidities, especially hypertension, diabetes, and thyroid disease (P < 0.05). Leukopenia was present in 32.1% of the convalescent patients and lymphocytopenia was present in 6.7%, both of which were more common in severe patients. 48 (35.8%) of discharged patients had elevated levels of alanine aminotransferase, which was more common in adults than in children (40.2% vs 13.6%, P = 0.018). A normal chest CT was found in 61 (45.5%) patients during rehabilitation. Severe patients had more ground-glass opacity, bilateral patchy shadowing, and fibrosis. No significant differences were observed in the positive rate of IgG and/or IgM antibodies between severe and non-severe patients.
CONCLUSION
CONCLUSIONS
Leukopenia, lymphopenia, ground-glass opacity, and fibrosis are common in discharged severe COVID-19 patients, and liver injury is common in discharged adult patients. We suggest physicians develop follow-up treatment plans based on the different clinical characteristics of convalescent patients.
Identifiants
pubmed: 33243228
doi: 10.1186/s12931-020-01580-0
pii: 10.1186/s12931-020-01580-0
pmc: PMC7689638
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
314Subventions
Organisme : Guizhou Science and Technology Department
ID : [2020]4Y170
Références
Clin Infect Dis. 2020 Nov 19;71(16):2027-2034
pubmed: 32221519
Lancet. 2020 Feb 22;395(10224):565-574
pubmed: 32007145
Clin Transl Immunology. 2020 May 06;9(5):e01136
pubmed: 32382418
JAMA. 2020 Mar 17;323(11):1061-1069
pubmed: 32031570
N Engl J Med. 2020 Apr 30;382(18):1708-1720
pubmed: 32109013
N Engl J Med. 2020 Feb 27;382(9):872-874
pubmed: 31991079
J Clin Virol. 2020 Jun;127:104364
pubmed: 32311650
Blood Cells Mol Dis. 2020 Jul;83:102437
pubmed: 32325421
J Med Virol. 2020 Jun;92(6):612-617
pubmed: 32108351
J Med Virol. 2020 May 23;:
pubmed: 32445489
Lancet. 2020 Feb 15;395(10223):497-506
pubmed: 31986264
Sci China Life Sci. 2020 Mar;63(3):364-374
pubmed: 32048163
J Infect. 2020 Jul;81(1):147-178
pubmed: 32283164
J Med Virol. 2020 Sep;92(9):1596-1602
pubmed: 32249943
PLoS One. 2016 Nov 3;11(11):e0165978
pubmed: 27812197
Lancet Respir Med. 2020 Apr;8(4):420-422
pubmed: 32085846
Infection. 2020 Jun;48(3):445-452
pubmed: 32301099
N Engl J Med. 2020 Feb 20;382(8):727-733
pubmed: 31978945
JAMA. 2020 Jun 16;323(23):2386-2387
pubmed: 32432681
J Med Virol. 2020 Apr;92(4):401-402
pubmed: 31950516
J Infect. 2020 Apr;80(4):388-393
pubmed: 32112884
N Engl J Med. 2020 Mar 5;382(10):929-936
pubmed: 32004427
Eur Rev Med Pharmacol Sci. 2020 Mar;24(6):3404-3410
pubmed: 32271459
Chin Med J (Engl). 2020 May 5;133(9):1032-1038
pubmed: 32118640
JCI Insight. 2019 Oct 17;4(20):
pubmed: 31550243
Respir Res. 2020 Mar 26;21(1):74
pubmed: 32216803
Eur Respir J. 2020 May 14;55(5):
pubmed: 32217650